Lehman Cuts Biotech Sector to Neutral

Analyst Craig Parker says he thinks current valuations have discounted positive attributes of the biotechnology sector

Lehman Brothers downgraded the biotech sector to neutral from positive. CancerVax (CNVX ) was one of the biotech stocks that fell on the comments.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.